Most importantly, this mechanism does not strictly depend on the reliance of tumor cells upon OxPhos and can be exploited to further enhance killing of MYC‐overexpressing cells by combining IACS‐010759 with other pro‐oxidant drugs, improving the therapeutic efficacy against high‐grade lymphomas. The gene discussed is MYC; the disease is neoplasm.